At the news
? BEARISHIMPACT 5/10 8-K filed Nov 9, 2026 at 08:05 ET
The BLA submission for TA-ERT remains on track for December 2026, and the company amended its Avenue loan to increase Tranche 2 availability to $15M and extended the interest-only period. The separation of the CRHX-101 program into Adrenyx Biosciences with a $5M initial note and planned distribution to shareholders is a strategic restructuring, but the widening net loss and cash burn of $24M in the quarter are the dominant financial facts.
- R&D expenses rose to $18.1M in Q3 2026 from $5.0M in Q3 2025, driven by TA-ERT manufacturing and clinical costs
- Cash and equivalents $87.7M at Sep 30, 2026, down from $96.3M at Jun 30, 2026; cash runway into H2 2027
- BLA submission for TA-ERT remains on track for December 2026 seeking accelerated approval for MPS IIIB
- Avenue Loan Agreement amended to increase Tranche 2 to $15M and extend interest-only period through March 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access